| 张瑞,颜程楠,刘飞雪,等.2023—2024 年济南市精神卫生中心口服抗精神病药应用情况分析[J].安徽医药,待发表. |
| 2023—2024 年济南市精神卫生中心口服抗精神病药应用情况分析 |
|
| 投稿时间：2025-10-10 录用日期：2025-11-17 |
| DOI： |
| 中文关键词: 抗精神病药，药物用量，用药频度，合理用药，利培酮片，奋乃静 |
| 英文关键词: |
| 基金项目:济南市卫生健康委员会科技发展计划项目(2024301026) |
|
| 摘要点击次数: 29 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：分析济南市精神卫生中心2023-2024年口服抗精神病药物的使用情况，评价其用药合理性，为临床用药优化提供参考。方法：采用回顾性研究方法，提取2023年6月至2024年5月医院his信息系统中11种口服抗精神病药物的使用数据，计算用药频度(DDDs)、限定日费用(DDDc)、排序比(B/A)及药物利用指数(DUI)，并基于多维度药物利用评价(DUE)模型对药物进行综合评分。结果: 口服抗精神病药物使用量呈逐渐上升趋势，非典型抗精神病药占主导地位，利培酮片DDDs持续居首。DUE评分显示，利培酮片(95分)和奋乃静片(94分)综合评分最高。部分药物存在剂量使用不合理现象(DUI偏离1.0)，且高DDDc药物患者经济负担较重。
结论：非典型抗精神病药在临床中占据主导地位，但其高DDDc值提示经济负担较重，本研究创新性地提出基于多维度评价的个体化用药方案，强调需结合患者病情、经济状况及药物安全性优化用药选择，同时加强药师监管和患者教育，以提升用药合理性。 |
| 英文摘要: |
| Objective: To analyze the utilization patterns of oral antipsychotics in Jinan Mental Health Centerfrom 2023 to 2024, assess the rationality of their use, and provide evidence-basedrecommendations for optimizing clinical medication strategies.Methods:A retrospective study was conducted using data extracted from the hospital's HIS on 11 oral antipsychotic drugs from June 2023 to May 2024. Keyindicators, including Defined Daily Doses (DDDs), Defined Daily Dose cost (DDDc), ranking ratio(B/A), and Drug Utilization index (DUI), were calculated. A comprehensive multi-dimensional DrugUse Evaluation (DUE) model was employed to assess the drugs.Results:The consumption of oral antipsychotics demonstrated a consistent quarterly increasingtrend. Atypical antipsychotics dominated clinical practice, with risperidone tablets consistentlyranking first in DDDs. Based on the DUE scores, risperidone tablets (92 points) and perphenazinetablets (89 points) achieved the highest comprehensive ratings. Irrational dosing patterns wereidentified for some medications (DUI deviating significantly from 1.0). Furthermore, drugs with highDDDc values posed a considerable economic burden to patients.
Conclusion: Atypical antipsychotics are the cornerstone of clinical treatment in our center.However, their high DDDc values highlight a significant cost burden. This study innovativelyproposes individualized medication plans based on a multidimensional evaluation frameworkemphasizing the need to tailor drug selection by integrating patient-specific factors, clinicalefficacy, economic considerations, and safety profiles. Strengthening pharmacist-led supervisionand patient education is also recommended to further enhance medication rationality. |
|
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
